Nuvalent is a Cambridge, Mass.-based biotechnology company creating precisely targeted small-molecule therapies against clinically validated kinase targets in cancer. The company leverages structure-based design to develop selective inhibitors intended to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC—NVL-520 (ROS1-selective) and NVL-655 (ALK-selective)—alongside multiple discovery-stage research programs. It plans to use the proceeds from its financing for clinical advancement of NVL-520 and NVL-655 and to expand and accelerate its discovery research pipeline. The company announced leadership additions including CEO James Porter, Ph.D., and Chief Medical Officer Christopher Turner, M.D., and expects Andrew Hack of Bain Capital Life Sciences to join its board following the financing. Nuvalent closed a $135M Series B financing. Nuvalent is a Cambridge, MA-based biotechnology company creating precisely targeted small-molecule therapies for clinically proven kinase targets in cancer. The company leverages structure-based drug design to develop selective kinase inhibitors intended to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent has launched a portfolio of kinase inhibitors with parallel lead programs in ROS1-positive and ALK-positive non-small cell lung cancer, including NUV-520 (a potential best-in-class ROS1-selective inhibitor) and NUV-655 (an ALK-selective inhibitor). It also maintains multiple discovery-stage research programs advancing its proprietary discovery efforts. The founding technology was developed under the guidance of Matthew Shair, Ph.D., who serves as Founder and Head Scientific Advisor, and James R. Porter, Ph.D., is CEO. Financially, the company completed a $50M Series A financing with an investment from Deerfield Management.

Total raised

$185M

Funding rounds

2

Latest round

Series B

Latest activity

May 2021